Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Revenue (ASC 606) of $263.50 million for fiscal year 2025.
IOVANCE BIOTHERAPEUTICS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $263.50M | +60.6% |
| 2024 | $164.07M | +13699.0% |
| 2023 | $1.19M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $67.45M | +15.2% | +12.5% |
| June 30, 2025 | $59.95M | +92.7% | +21.5% |
| March 31, 2025 | $49.32M | +6798.5% | -15.8% |
| September 30, 2024 | $58.55M | +12385.1% | +88.2% |
| June 30, 2024 | $31.11M | +12969.7% | +4250.5% |
| March 31, 2024 | $715.0K | — | +52.5% |
| September 30, 2023 | $469.0K | — | +97.1% |
| June 30, 2023 | $238.0K | — | — |
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +60.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, IOVANCE BIOTHERAPEUTICS, INC.’s revenue (asc 606) has grown by 22061.6% (from $1.19 million to $263.50 million).
- The most recent figure is from IOVANCE BIOTHERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: